Clinician.com

Here's what we learned from the latest outbreak.

Clinical Briefs

In this section: improving cardiovascular outcomes through early treatment of diabetes; re-thinking PTSD treatment in veterans; and a link between rosacea and cardiovascular disease.

Flibanserin Tablets (Addyi)

The FDA has approved the first drug for the treatment of hypoactive sexual desire disorder in women.

The Impact of Hypoglycemia on Renal Impairment

A retrospective cohort study evaluated renal function data of 101 patients with type 2 diabetes and a history of severe hypoglycemia compared with a matched group of individuals with type 2 diabetes with no history of hypoglycemia.

Efficacy and Safety of Very Early Mobilization After Onset of Acute Stroke

The higher dose, very early (within 24 hours) mobilization protocol was associated with a reduction in the odds of a favorable outcome at 3 months after stroke occurrence.

Researchers accused of unethical practices: Psychiatric patients “extremely vulnerable”

In 2003, psychiatric researchers at the University of Minnesota recruited a mentally ill young man, Dan Markingson, into a study on an antipsychotic drug. Months later, the patient violently committed suicide; multiple allegations of unethical practices ensued.

SPRINT: The Systolic Blood Pressure Trial or ‘How Low Do You Go?’

Designed to see if lower blood pressures reduced the risk of blood pressure-related health outcomes, the NIH ended the SPRINT trial early and issued a news release that a lower blood pressure target significantly reduces cardiovascular complications in adults age 50 and older with high blood pressure.